Loading...
Withdrawing Winnings
Special Features
Investment2020-06-26T13:27:52+00:00

Innovating for Investors

A new investment model

Investing in Inventionshare offers substantial benefits compared to investing in an operating company. While there is technology risk in both, the product execution risk is substantially higher in an operating company compared to validating the underlying technology and finding applications. The capital requirement for technology commercialization is a small fraction of an operating company productization and market development budget. And the capital efficiency of our technology commercialization model allows for much higher levels of diversification.

The time to realizing an investment return is also much shorter. An operating company investment exit can often take 10 to 15 years. By contrast the InventionShare model acquires an equity interest in a compelling platform technology that is packaged into vertical and horizontal spinouts with a goal of selling in 2-5 years while retaining a trailing interest.

InventionShare offers investors several options to gain capital efficient exposure to specific markets. Investing in InventionShare directly offers exposure to all of its subsidiary markets. Investment in application-specific subsidiaries provides very targeted exposure to individual vertical and horizontal markets. Finally, InventionShare is partnering to form specialized funds that inject InventionShare technology into companies that are lagging in their industries due to uncompetitive technology. These injection funds will also have a social impact mandate.

A new investment model

Investing in Inventionshare offers substantial benefits compared to investing in an operating company. While there is technology risk in both, the product execution risk is substantially higher in an operating company compared to validating the underlying technology and finding applications. The capital requirement for technology commercialization is a small fraction of an operating company productization and market development budget. And the capital efficiency of our technology commercialization model allows for much higher levels of diversification.

The time to realizing an investment return is also much shorter. An operating company investment exit can often take 10 to 15 years. By contrast the InventionShare model acquires an equity interest in a compelling platform technology that is packaged into vertical and horizontal spinouts with a goal of selling in 2-5 years while retaining a trailing interest.

InventionShare offers investors several options to gain capital efficient exposure to specific markets. Investing in InventionShare directly offers exposure to all of its subsidiary markets. Investment in application-specific subsidiaries provides very targeted exposure to individual vertical and horizontal markets. Finally, InventionShare is partnering to form specialized funds that inject InventionShare technology into companies that are lagging in their industries due to uncompetitive technology. These injection funds will also have a social impact mandate.

We’re not a VC

Let’s contrast our investment model with a conventional Venture Capital approach.

Venture capital funds often invest in pre-revenue, capital-hungry startups that face a long hard road to viability. Along the way they will encounter many challenges and likely a number of capitalization stages, each of which creates dilution for the investors. And the path to an exit is very uncertain with a high proportion of failures.

By contrast, our technology injection approach focuses on existing revenue-generating companies that have a specific technology problem that we can solve. Our solution requires a relatively small amount of capital that is invested with terms and conditions that support a specific turnaround formula. In this way, our approach will be composed of many low-risk investments that deliver predictable returns in relatively short timeframes.

We’re not a VC

Let’s contrast our investment model with a conventional Venture Capital approach.

Venture capital funds often invest in pre-revenue, capital-hungry startups that face a long hard road to viability. Along the way they will encounter many challenges and likely a number of capitalization stages, each of which creates dilution for the investors. And the path to an exit is very uncertain with a high proportion of failures.

By contrast, our technology injection approach focuses on existing revenue-generating companies that have a specific technology problem that we can solve. Our solution requires a relatively small amount of capital that is invested with terms and conditions that support a specific turnaround formula. In this way, our approach will be composed of many low-risk investments that deliver predictable returns in relatively short timeframes.

“If I had asked the public what they wanted, they would have said a faster horse.”

— Henry Ford